
Quarterly report 2024-Q3
added 11-07-2024
Avinger Revenue 2011-2026 | AVGR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.65 M | 8.27 M | 10.1 M | 8.76 M | 9.13 M | 7.92 M | 9.93 M | 19.2 M | 10.7 M | 11.2 M | 13 M | 8.56 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | 7.65 M | 10.4 M |
Quarterly Revenue Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 1.85 M | 1.86 M | - | 1.82 M | 2.04 M | 1.89 M | - | 2.25 M | 2.13 M | 1.89 M | - | 2.37 M | 2.8 M | 2.56 M | - | 2.3 M | 1.47 M | 2.26 M | - | 2.41 M | 2.32 M | 1.84 M | - | 2.02 M | 2.06 M | 1.81 M | - | 2.07 M | 2.46 M | 3.49 M | 4.68 M | 5.32 M | 4.68 M | 4.54 M | 2.86 M | 2.72 M | 3.05 M | 2.09 M | 3.07 M | 2.63 M | 3.39 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.32 M | 1.47 M | 2.58 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 173.14 | -0.8 % | $ 13 B | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 279.25 | 0.63 % | $ 7.88 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 10.9 | -1.54 % | $ 1.64 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.17 | -0.41 % | $ 1.64 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 0.84 % | $ 38 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.3 | -1.79 % | $ 124 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 37.59 | -1.03 % | $ 5.6 K | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.79 | 0.83 % | $ 91.5 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.89 | - | $ 1.15 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | -3.86 % | $ 16.9 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 8.68 | -3.12 % | $ 246 M | ||
|
Electromed
ELMD
|
64 M | $ 24.12 | -1.19 % | $ 204 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.97 | 0.19 % | $ 375 M | ||
|
Inogen
INGN
|
349 M | $ 6.33 | -4.95 % | $ 168 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 62.78 | -0.93 % | $ 3.42 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.7 | 4.4 % | $ 68.2 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.42 | -1.07 % | $ 12.2 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.11 | -0.96 % | $ 870 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.04 | 1.62 % | $ 360 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.69 | -1.43 % | $ 28.9 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.02 | -4.71 % | $ 1.59 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.74 | -0.51 % | $ 1.14 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.11 | -1.8 % | $ 2.96 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.68 | 0.38 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 77.87 | -1.62 % | $ 45.5 B |